The study investigated TRPC6 inhibition with BI 764198 for the treatment of focal segmental glomerulosclerosis (FSGS) in a randomized, placebo-controlled phase 2 trial. BI 764198 reduced proteinuria in patients. The drug was well tolerated by the study participants. This is the first evidence of the efficacy of podocyte-targeted therapy in FSGS. Larger randomized controlled trials are planned to evaluate the safety and efficacy of BI 764198 in FSGS and other conditions affected by podocytopathy. These will have longer treatment durations and allow for meaningful subgroup analyses.